FDA approves Vitrakvi for cancers with certain genetic trait
(HealthDay)—Vitrakvi (larotrectinib) has been approved by the U.S. Food and Drug Administration to treat adult and pediatric patients whose cancers have a specific genetic feature.
Nov 28, 2018
0
25